Amyloid-β42 alters apolipoprotein E solubility in brains of mice with five familial AD mutations

Journal of Neuroscience Methods

Volumn 196, Issue 1, 2011, Pages 51-59

  Youmans, Katherine Lynn ^a   Leung, Steffi ^a   Zhang, Juan ^c   Maus, Erika ^b   Baysac, Kathleen ^c   Bu, Guojun ^c,d   Vassar, Robert ^b   Yu, Chunjiang ^a   LaDu, Mary Jo ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MAYO CLINIC   (United States)

Author keywords

5xFAD; Alzheimer's disease; ApoE; Detergent; Solubility

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; HIPPOCAMPUS; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; SOLUBILITY; WESTERN BLOTTING;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOLIPOPROTEINS E; BRAIN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMANS; MICE; MICE, INBRED C57BL; MUTATION; PEPTIDE FRAGMENTS; PRESENILIN-1;

EID: 79951551687     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2010.12.025     Document Type: Article

References (58)

1. Aoki M., Volkmann I., Tjernberg L.O., Winblad B., Bogdanovic N. Amyloid beta-peptide levels in laser capture microdissected cornu ammonis 1 pyramidal neurons of Alzheimer's brain. Neuroreport 2008, 19:1085-1089.
2. Bales K.R., Liu F., Wu S., Lin S., Koger D., DeLong C., et al. Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J Neurosci 2009, 29:6771-6779.
3. Belinson H., Lev D., Masliah E., Michaelson D.M. Activation of the amyloid cascade in apolipoprotein E4 transgenic mice induces lysosomal activation and neurodegeneration resulting in marked cognitive deficits. J Neurosci 2008, 28:4690-4701.
4. Brecht W.J., Harris F.M., Chang S., Tesseur I., Yu G.Q., Xu Q., et al. Neuron-specific apolipoprotein E4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci 2004, 24:2527-2534.
5. Burgess B.L., Parkinson P.F., Racke M.M., Hirsch-Reinshagen V., Fan J., Wong C., et al. ABCG1 influences brain cholesterol synthesis but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo. J Lipid Res 2008, 49:1254-1267.
6. Bush A.I., Martins R.N., Rumble B., Moir R., Fuller S., Milward E., et al. The amyloid precursor protein of Alzheimer's disease is released by human platelets. J Biol Chem 1990, 265:15977-15983.
7. Caselli R.J., Walker D., Sue L., Sabbagh M., Beach T. Amyloid load in nondemented brains correlates with APOE E4. Neurosci Lett 2010, 473:168-171.
8. Cataldo A.M., Petanceska S., Terio N.B., Peterhoff C.M., Durham R., Mercken M., et al. Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. Neurobiol Aging 2004, 25:1263-1272.
9. Christensen D.Z., Schneider-Axmann T., Lucassen P.J., Bayer T.A., Wirths O. Accumulation of intraneuronal Abeta correlates with ApoE4 genotype. Acta Neuropathol 2010, 119:555-566.
10. Cizas P., Budvytyte R., Morkuniene R., Moldovan R., Broccio M., Losche M., et al. Size-dependent neurotoxicity of beta-amyloid oligomers. Arch Biochem Biophys 2010, 496:84-92.
11. Counts S.E., Nadeem M., Lad S.P., Wuu J., Mufson E.J. Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment. J Neuropathol Exp Neurol 2006, 65:592-601.
12. Dahlgren K.N., Manelli A.M., Stine W.B., Baker L.K., Krafft G.A., LaDu M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 2002, 277:32046-32053.
13. David H.A., Gunnink J.L. The paired t test under artificial pairing. Am Statist 1997, 51:9-12.
14. Delacourte A., Sergeant N., Champain D., Wattez A., Maurage C.A., Lebert F., et al. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology 2002, 59:398-407.
15. Di Luca M., Pastorino L., Bianchetti A., Perez J., Vignolo L.A., Lenzi G.L., et al. Differential level of platelet amyloid beta precursor protein isoforms: an early marker for Alzheimer disease. Arch Neurol 1998, 55:1195-1200.
16. Durakoglugil M.S., Chen Y., White C.L., Kavalali E.T., Herz J. Reelin signaling antagonizes beta-amyloid at the synapse. Proc Natl Acad Sci USA 2009, 106:15938-15943.
17. Elliott D.A., Tsoi K., Holinkova S., Chan S.L., Kim W.S., Halliday G.M., et al. Isoform-specific proteolysis of apolipoprotein-E in the brain. Neurobiol Aging 2009, 32:257-271.
18. Gouras G.K., Tampellini D., Takahashi R.H., Capetillo-Zarate E. Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol 2010, 119:523-541.
19. Han S.-H., Hulette C., Saunders A.M., Einstein G., Pericak-Vance M., Strittmatter W.J., et al. Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls. Exp Neurol 1994, 128:13-26.
20. Hashimoto T., Wakabayashi T., Watanabe A., Kowa H., Hosoda R., Nakamura A., et al. CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXV. EMBO J 2002, 21:1524-1534.
21. Hirsch-Reinshagen V., Maia L.F., Burgess B.L., Blain J.F., Naus K.E., McIsaac S.A., et al. The absence of ABCA1 decreases soluble apoE levels but does not diminish amyloid deposition in two murine models of Alzheimer's disease. J Biol Chem 2005, 280:43243-43256.
22. Kawarabayashi T., Shoji M., Younkin L.H., Wen-Lang L., Dickson D.W., Murakami T., et al. Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 2004, 24:3801-3809.
23. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 2001, 21:372-381.
24. Kim J., Basak J.M., Holtzman D.M. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009, 63:287-303.
25. Klein W.L., Krafft G.A., Finch C.E. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci 2001, 24:219-224.
26. Koob A.O., Paulino A.D., Masliah E. GFAP reactivity, apolipoprotein E redistribution and cholesterol reduction in human astrocytes treated with alpha-synuclein. Neurosci Lett 2010, 469:11-14.
27. Krul E., Cole T. Quantitation of apolipoprotein E. Methods in enzymology 1996, Academic Press, New York, p. 170-87.
28. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
29. Lippel K., Tyroler H.A., Gotto A., Brewer H.B., Albers J.J., Scanu A., et al. Workshop on apolipoprotein quantification. Arteriosclerosis 1983, 3:452-464.
30. Liu Q., Zerbinatti C.V., Zhang J., Hoe H.S., Wang B., Cole S.L., et al. Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 2007, 56:66-78.
31. Love S., Siew L.K., Dawbarn D., Wilcock G.K., Ben-Shlomo Y., Allen S.J. Premorbid effects of APOE on synaptic proteins in human temporal neocortex. Neurobiol Aging 2006, 27:797-803.
32. Manelli A.M., Bulfinch L.C., Sullivan P.M., LaDu M.J. Abeta42 neurotoxicity in primary co-cultures: effect of apoE isoform and Abeta conformation. Neurobiol Aging 2007, 28:1139-1147.
33. Mastrangelo M.A., Bowers W.J. Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice. BMC Neurosci 2008, 9:81.
34. Morishima-Kawashima M., Oshima N., Ogata H., Yamaguchi H., Yoshimura M., Sugihara S., et al. Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain. Am J Pathol 2000, 157:2093-2099.
35. Naidu A., Catalano R., Bales K., Wu S., Paul S.M., Cordell B. Conversion of brain apolipoprotein E to an insoluble form in a mouse model of Alzheimer disease. Neuroreport 2001, 12:1265-1270.
36. Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 2006, 26:10129-10140.
37. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
38. Ohno M., Chang L., Tseng W., Oakley H., Citron M., Klein W.L., et al. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. Eur J Neurosci 2006, 23:251-260.
39. Patton R.L., Kalback W.M., Esh C.L., Kokjohn T.A., Van Vickle G.D., Luehrs D.C., et al. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol 2006, 169:1048-1063.
40. Potempska A., Styles J., Mehta P., Kim K.S., Miller D.L. Purification and tissue level of the beta-amyloid peptide precursor of rat brain. J Biol Chem 1991, 266:8464-8469.
41. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N Engl J Med 2010, 362:329-344.
42. Schmitz C., Rutten B.P., Pielen A., Schafer S., Wirths O., Tremp G., et al. Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am J Pathol 2004, 164:1495-1502.
43. Sullivan P.M., Han B., Liu F., Mace B.E., Ervin J.F., Wu S., et al. Reduced levels of human apoE4 protein in an animal model of cognitive impairment. Neurobiol Aging 2009.
44. Sullivan P.M., Mace B.E., Maeda N., Schmechel D.E. Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice. Neuroscience 2004, 124:725-733.
45. Sullivan P.M., Mezdour H., Aratani Y., Knouff C., Najib J., Reddick R.L., et al. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem 1997, 272:17972-17980.
46. Thal D.R., Capetillo-Zarate E., Del Tredici K., Braak H. The development of amyloid beta protein deposits in the aged brain. Sci Aging Knowledge Environ 2006, 2006:re1.
47. Thal D.R., Griffin W.S., Braak H., Parenchymal, vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. J Cell Mol Med 2008, 12:1848-1862.
48. Tomiyama T., Matsuyama S., Iso H., Umeda T., Takuma H., Ohnishi K., et al. A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci 2010, 30:4845-4856.
49. Van Nostrand W.E., Farrow J.S., Wagner S.L., Bhasin R., Goldgaber D., Cotman C.W., et al. The predominant form of the amyloid beta-protein precursor in human brain is protease nexin 2. Proc Natl Acad Sci USA 1991, 88:10302-10306.
50. Wahrle S.E., Jiang H., Parsadanian M., Kim J., Li A., Knoten A., et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 2008, 118:671-682.
51. Wahrle S.E., Shah A.R., Fagan A.M., Smemo S., Kauwe J.S., Grupe A., et al. Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms. Mol Neurodegener 2007, 2:7.
52. Weidemann A., Konig G., Bunke D., Fischer P., Salbaum J.M., Masters C.L., et al. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell 1989, 57:115-126.
53. Wisniewski T., Lalowski M., Golabek A., Vogel T., Frangione B. Is Alzheimer's disease an apolipoprotein E amyloidosis?. Lancet 1995, 345:956-958.
54. Youmans KL. The effects of human apoE on amyloid-beta (42) pathology and synaptic loss in a novel transgenic mouse model. American Society for Neurochemistry. Transactions of the American Society for Neurochemistry: Santa Fe, NM; 2010.
55. Yu C., Nwabuisi-Heath E., Laxton K., Ladu M.J. Endocytic pathways mediating oligomeric Abeta42 neurotoxicity. Mol Neurodegener 2010, 5:19.
56. Yu C., Youmans K.L., Ladu M.J. Proposed mechanism for lipoprotein remodelling in the brain. Biochim Biophys Acta 2010, 1801:819-823.
57. Zerbinatti C.V., Wahrle S.E., Kim H., Cam J.A., Bales K., Paul S.M., et al. Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Abeta42 accumulation in amyloid model mice. J Biol Chem 2006, 281:36180-36186.
58. Zhao J., Fu Y., Yasvoina M., Shao P., Hitt B., O'Connor T., et al. Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. J Neurosci 2007, 27:3639-3649.